# Improving 10-year cardiovascular risk prediction in patients with type 2 diabetes with metabolomics

Ruijie Xie a,b, Teresa Seum,b, Sha Sha Sha Sha Sha Frares Bernd Holleczek, Hermann Brenner, Ben Schöttker<sup>a</sup>

<sup>a</sup> Division of Clinical Epidemiology and Aging Research, German Cancer Research Center, Im Neuenheimer Feld 581, 69120 Heidelberg, Germany

<sup>b</sup> Faculty of Medicine, University of Heidelberg, 69115 Heidelberg, Germany

<sup>c</sup> Saarland Cancer Registry, Neugeländstraße 9, 66117 Saarbrücken, Germany

Laboratory or institution of origin: Division of Clinical Epidemiology and Aging Research, German Cancer Research Center, Baden-Württemberg, 69120, Heidelberg, Germany

Correspondence to: Ben Schöttker, PhD, Im Neuenheimer Feld 581, 69120, Heidelberg, Germany, Tel.: +49-6221421355, Fax: +49-6221421302, E-mail: b.schoettker@dkfz.de

Word count: 3,423

Number of tables and figures: 4

### **Twitter Summary**

Study shows: metabolites measured in blood samples enhance cardiovascular risk prediction for patients with type 2 diabetes.

**Abstract** 

**Background and Aims** 

To evaluate the potential of improved prediction of the 10-year risk of major adverse

cardiovascular events (MACE) in patients with type 2 diabetes by adding metabolomic

biomarkers to the SCORE2-Diabetes model.

Methods

Data from 10,257 and 1,039 patients with type 2 diabetes from the UK Biobank (UKB) and

the German ESTHER cohort, respectively, were used for model derivation, internal and

external validation. A total of 249 metabolites were measured with nuclear magnetic

resonance (NMR) spectroscopy. LASSO regression with bootstrapping was used to identify

metabolites in sex-specific analyses and the predictive performance of metabolites added to

the SCORE2-Diabetes model was primarily evaluated with Harrell's C-index.

**Results** 

Seven metabolomic biomarkers were selected by LASSO regression for enhanced MACE risk

prediction (three for both sexes, three male- and one female-specific metabolite(s)).

Especially albumin and the omega-3-fatty-acids-to-total-fatty-acids-percentage among males

and lactate among females improved the C-index. In internal validation with 30% of the

UKB, adding the selected metabolites to the SCORE2-Diabetes model increased the C-index

statistically significantly (P=0.034) from 0.660 to 0.680 in the total sample. In external

validation with ESTHER, the C-index increase was higher (+0.041) and remained statistically

2

significant (*P*=0.015).

**Conclusions** 

Incorporating seven metabolomic biomarkers in the SCORE2-Diabetes model enhanced its

ability to predict MACE in patients with type 2 diabetes. Given the latest cost reduction and

standardization efforts, NMR metabolomics has the potential for translation into the clinical

routine.

**Keywords:** Type 2 diabetes, metabolomics, cardiovascular risk, prediction model

Introduction

Cardiovascular diseases (CVDs) remain the leading cause of death in Europe, contributing to

over 60 million potential life-years lost annually (1). In particular, individuals with type 2

diabetes have an increased incidence of CVD, with a risk profile that differs significantly

from the general population (2). In light of this, identifying high-risk subgroups offers

potentials for optimizing healthcare resource allocation and initiating preventive strategies

against CVD events (3).

To further refine this cardiovascular risk evaluation specifically for people with type 2

diabetes, the SCORE2-Diabetes model became available in 2023 (4). It was designed to

stratify individuals with type 2 diabetes into distinct risk categories based on their 10-year risk

of major adverse cardiovascular events (MACE). Despite the advancement by the SCORE2-

Diabetes model, a need for an enhanced precision in risk evaluation for this susceptible

population still persists (5).

Metabolomics offers an unrivaled perspective through analyzing minuscule molecular

metabolites within specific tissues or biofluids. It resonates with the genetic, environmental,

and pathophysiological alterations characterizing the progression of type 2 diabetes and CVD

(6). Harnessing such insights holds promise to enhance the predictive capacities of traditional

prediction models by unveiling metabolites intrinsically associated with CVD risk.

Although several studies have examined the role of metabolites in improving the prediction of

MACE in patients with type 2 diabetes, most were limited by small sample size, short follow-

up durations, and a lack of validation in external cohorts (7-10). Additionally, emerging

evidence emphasizes that there are sex differences in the associations of some metabolites

with MACE but past studies have typically used sex as a covariate rather than selecting

4

metabolomic biomarkers based on sex specificity (11; 12).

The present study aimed to leverage data from two large European cohorts to select

metabolomic biomarkers based on a sex-specific selection and to assess whether integration

of these metabolomic biomarkers improve the predictive power of the SCORE2-Diabetes

model for a 10-year cardiovascular risk assessment.

**Methods** 

Study design and population

The UK Biobank (UKB), a large prospective cohort in the United Kingdom, aims to bolster

knowledge, preventive measures, diagnostic modalities, and therapeutic approaches across

diverse disease spectra (13). In brief, between 13 March 2006 and 1 October 2010, over half

million participants aged 37-73 were enrolled across England, Scotland, and Wales.

The ESTHER study is a large population-based cohort study conducted in Saarland,

Germany. Participants aged between 50 and 75 years were recruited during a regular health

check by local general practitioners (GP) between 1 July 2000 and 30 June 2002. After that,

participants were followed up every two to three years. The study effectively collected data on

9,940 participants (14; 15).

**Metabolites quantification** 

Nightingale Health's high-throughput nuclear magnetic resonance (NMR) metabolomics

platform performed the metabolomic profiling on 274,353 baseline plasma samples from

randomly selected UKB participants, alongside all available 8,308 baseline serum samples

from the ESTHER cohort with sufficient blood sample quality (16). This process enabled the

quantification of 250 metabolomic biomarkers, including lipids, fatty acids, amino acids,

ketone bodies, and other essential low-molecular-weight markers (17). However, glycerol was

excluded because it could not be measured in most of the participants of both cohorts, leaving

n=249 metabolites for the analyses. The nomenclature and completeness of these metabolites

are shown in **Supplemental Table S1**.

Variables of the SCORE2-Diabetes model

The SCORE2-Diabetes is a sex-specific competing risk-adjusted algorithm recently

developed and validated by the European Society of Cardiology, designed for adults with type

2 diabetes aged 40 to 69 years, includes age, sex, systolic blood pressure (SBP), smoking

status, age at diabetes diagnosis, HbA1c, and the estimated glomerular filtration rate (eGFR)

(4).

Information on demographic characteristics, lifestyle factors and medical history, including

age, sex, age at diabetes diagnosis and smoking status (current or non-current) was collected

by standardized questionnaires in both cohorts. The SBP measurements were conducted by

automated reading of the Omron digital blood pressure monitor at the left upper arm in UKB

and from the physician's medical conditions report of the health check-up in the ESTHER

study. The laboratory methods used to measure HDL-C, total cholesterol, HbA1c and

creatinine in both cohorts are shown in **Supplemental Table S2**. The eGFR was calculated

from creatinine values using the CKD-Epi 2009 equation in both cohorts (18).

**Outcome assessment** 

The primary outcome was MACE, which included cardiovascular mortality, non-fatal

myocardial infarction, and non-fatal stroke (see detailed definition in Supplemental Table

S3). It was constructed in line with the endpoint definition used to derive the SCORE2-

Diabetes model. The only exception was that the non-fatal stroke definition was broader in the

ESTHER study because stroke subtypes cannot be distinguished in this cohort.

In the UKB cohort, non-fatal myocardial infarction and or non-fatal stroke were identified

from primary care records or hospital episode statistics. The date and cause of death were

determined by referring to death registries of the National Health Service Information Centre

for participants in the UKB study from England and Wales, and the National Health Service

Central Register of Scotland for those from Scotland.

As previously described (19), study participants from the ESTHER study reported on the

occurrence of incident myocardial infarction and stroke in standardized questionnaires at 2-,

5, 8-, and 11-year follow-ups. Self-reported cases underwent validation by the dissemination

of standardized questionnaires to the GPs of the study participants. The proportions of

physician-validated incident myocardial infarction (MI) and stroke cases were 89% and 91%,

respectively. A vital status inquiry was made at registration offices of residents, with death

certificates of deceased individuals being procured from local health authorities.

The follow-up period extended until the first recorded non-fatal myocardial infarction, non-

fatal stroke, death, or the end of the event registration period, which was capped at ten years

(4).

In- and exclusion criteria

We included n=10,257 and n=1,039 individuals with type 2 diabetes and measured

metabolomics data from the UKB and ESTHER study, respectively (Supplemental Figure

S1). Subjects with potential type 1 diabetes, ascertained by diabetes diagnosis before the  $40^{th}$ 

birthday, were excluded. UKB participants outside the age range of 50-74 years were

excluded to make the age distribution of two cohorts comparable. Furthermore, those with a

history of myocardial infarction or stroke before baseline or with a missing date on these

events of interest were excluded.

Statistical analyses

**General remarks** 

All analyses were conducted using R software, version 4.3.0 (R Foundation for Statistical

Computing, Vienna, Austria), with statistical significance set at P-values<0.05 for two-sided

tests. Missing values were imputed using the random forest imputation method, as

implemented in the r-package missForest (version 1.5) (20). Most variables of the SCORE2-

Diabetes model and the NMR metabolites were complete. Supplemental Table S1 illustrates

that the highest missing value rate was observed for HbA1c in the UKB at 5.1%. In the

ESTHER study, aside from the age at diabetes diagnosis (39.6%), no other variable's missing

rate exceeded 10%.

Metabolites selection and model derivation

Initially, all metabolite concentrations underwent log-transformation to approximate normal

distributions for analysis. These measures were then scaled to standard deviation units

independently within each cohort. The UKB dataset was partitioned into a derivation set

(70%) and an internal validation set (30%); the ESTHER study served as the external

validation cohort. The derivation set was used for metabolite selection and model derivation.

The Least Absolute Shrinkage and Selection Operator (LASSO), a regularization technique

adept at identifying strong predictors among high-dimensional and correlated predictors, was

implemented via the r-package glmnet (version 4.1-7) (21). Ten-fold cross-validation was

employed to determine the optimal tuning parameter  $\lambda$  for LASSO, based on the lowest model

validation error. A bootstrap LASSO approach was then undertaken, involving the creation of

1000 derived sets with the LASSO procedure applied to each resampled dataset (22).

Metabolites selected by LASSO in at least 95% of instances were designated as our

metabolites of interest, a threshold adopted from a previous study (23) to enhance model

generalization and mitigate overfitting. These selected metabolites were subsequently

incorporated into the SCORE2-Diabetes model to construct new sex-specific competing risk

models using the r-package *cmprsk* (version 2.2-11).

Model predictive performance validation

The predictive performance of the derived model was validated by using 30% of the UKB as

the internal validation cohort and the ESTHER cohort as the external validation cohort. The

incremental discrimination contributed by each metabolite was evaluated based on the internal

validation results.

Discriminative ability was assessed using Harrell's C-index, adjusted for competing risks (via

the r-package riskRegression, version 2023.03.2) (24). Furthermore, the net reclassification

index (NRI) and the integrated discrimination improvement (IDI) were evaluated for the final

model (using the r-package nricens, version 1.6) (25). Pre-specified CVD risk categories (0-

10%, >10-20%, and >20%) were employed for the NRI to indicate the proportion of

individuals correctly reclassified compared with the SCORE2-Diabetes model. Model

calibration was examined by plotting observed MACE event rates against predicted event

rates across deciles of absolute predicted risk.

Associations of selected metabolites with MACE

To elucidate the hazard ratios (HRs) and 95% confidence intervals (CIs) of selected

metabolites (per one standard deviation increment) for enhanced 10-year MACE prediction in

male and female patients with type 2 diabetes, metabolites were individually added to Cox

proportional hazards regression models in the derivation cohort, the internal validation cohort,

and the external validation cohort, respectively. These models were adjusted for SCORE2-

Diabetes model variables, using the r-package survival (version 3.5-5). The Benjamini-

Hochberg procedure was applied to control the false discovery rate (FDR) in this analysis.

Results

**Baseline characteristics and MACE case numbers** 

Table 1 summarizes the characteristics of the participants for all variables of the SCORE2-

Diabetes model from the 10,257 and 1,039 included participants with type 2 diabetes from the

UKB and ESTHER cohorts, respectively. The included UKB participants had an average age

of 61.5 years (SD 5.2), with males constituting 59.9% of the cohort. Over a follow-up time

limited to 10 years, 1,366 MACE events were recorded in the UKB. The ESTHER sample

had a mean age of 64.0 years (SD 6.3), and 50.8% of participants were males. During the first

10

10 years of ESTHER follow-up, 175 MACE events were recorded.

Associations of metabolomic biomarkers with MACE

A total of 7 metabolites were selected to enhance MACE risk prediction in the SCORE2-

diabetes model in the UKB cohort by LASSO analyses and bootstrapping with a frequency of

more than 950 times in the 1000 replicate selection (Supplemental Table S4). Of these

metabolites, three metabolites improved MACE risk prediction in both men and women

(creatinine, albumin, and GlycA (glycoprotein acetyls)). Furthermore, lactate emerged as an

additional predictive metabolite solely in women, while the three metabolites - acetate,

VLDL-size (the average diameter for very low-density lipoprotein particles), and Omega-3-

pct (the Omega-3 fatty acids to total fatty acids percentage) exhibited enhanced predictive

capabilities exclusively in males.

**Figure 1** shows the associations of the 7 selected metabolites with MACE in multivariate Cox

regression models adjusted for SCORE2-Diabetes model variables separately in males and

females in the derivation cohort. GlycA, and creatinine were positively, and omega-3-pct and

albumin were inversely, statistically significantly associated with MACE at an FDR-adjusted

P<0.05 level in both sexes. The results were generally consistent in the internal validation

cohort but some results differed like for lactate for which results showed a sex difference in

the internal validation study (Supplemental Figure S2) which was not seen in the derivation

cohort (Figure 1) or the external validation cohort (Supplemental Figure S3). With the

lower sample size of the ESTHER study, of the 7 metabolites, only albumin was statistically

11

significantly associated with MACE in males.

MACE risk prediction by metabolomic biomarkers

Figure 2 displays the incremental improvement in the C-statistic upon the sequential

inclusion of the selected 7 metabolites into the models for males and females one by one in

the internal validation set. Especially, the addition of albumin and Omega-3-pct significantly

improved discrimination power in males. GlycA, creatinine, acetate, and VLDL-size showed

notable but non-significant enhancements in males. In females, only lactate exhibited a

notable, yet non-significant, C-index increase.

**Table 2** presents the predictive performance metrics of the SCORE2-Diabetes model for 10-

year MACE risk prediction when used in combination with the 7 metabolomic biomarkers.

The coefficients of all variables required for calculation of the extended risk model are shown

in Supplemental Table S4. In the derivation set, by adding the selected metabolites, the C-

index (95% CI) of the SCORE2-Diabetes model statistically significantly improved

(P=0.008) from 0.662 (0.644-0.681) to 0.677 (0.659-0.696) in the total sample (**Table 2**). The

C-index increase was more pronounced in males (+0.017) than females (+0.007), with

statistical significance solely noted for males (P = 0.020). Internal validation in the UKB

yielded very similar results for the C-indices. Notably, an enhancement in risk reclassification

statistics was primarily observed in female participants with a statistically significant IDI.

Model calibration was comparably good for the SCORE2-Diabetes and the extended model in

the internal validation set (**Supplemental Figure S4**).

In the external validation with the total ESTHER study, the model demonstrated an even

greater improvement in discriminatory power compared to the UKB, with a likewise

statistically significant result (the C-index increased from 0.612 to 0.653, P=0.015; **Table 2**).

C-index increases were comparable for men (+0.031) and women (+0.030). Beyond these

improvements, the reclassification metrics for males indicated that 9.6% of events were

correctly reclassified by the extended model compared with the SCORE2-Diabetes model

[NRI= 9.6% (0.9%, 16.1%)]. In males, the SCORE2-Diabetes model showed a good

calibration, which was even better with the extended model (Supplemental Figure S5). In

women, the SCORE2-Diabetes model was slightly better calibrated than the extended model.

However, the MACE case number was quite low for female patients with type 2 diabetes in

the ESTHER cohort (n=68), which should be taken into consideration when interpreting the

figure.

**Discussion** 

Using large-scale data from two European cohorts of middle-aged and older patients with type

2 diabetes, we developed and validated a sex-specific competing risk algorithm that combines

the SCORE2-Diabetes model with 7 metabolites to improve 10-year cardiovascular risk

prediction. In internal and external validations, the C-index of the SCORE2-Diabetes model

significantly increased by 0.020 and 0.041, respectively.

**Comparison with previous studies** 

There are a limited number of studies using metabolomics to predict cardiovascular risk in

patients with type 2 diabetes. Three studies based on the ADVANCE trial (sample size:

n=3,576-3,779, follow-up: 5 years) investigated the association of specific types of fatty

acids, amino acids, and sphingolipids with cardiovascular events and demonstrated the

predictive value of these metabolites for cardiovascular risk in patients with type 2 diabetes

(9; 10; 26). However, the enhancement of the predictive ability of the original models by

these metabolomic biomarkers was relatively modest, with improvements in the C-statistic

ranging between 0.005 and 0.020. This limited enhancement could be attributed to the

investigation focusing only on a selection of a few metabolites. In contrast, the Edinburgh

Type 2 Diabetes Study (sample size: n=1,066, follow-up: 10 years) used a broader

metabolomics assay with 228 metabolites (23). By integrating 12 selected metabolites into

the reference model, there was a notable increase in the C-statistic by 0.019; which was

comparable to our findings. However, the models derived from the ADVANCE trial and the

Edinburgh Type 2 Diabetes Study lacked external validation and their metabolomics

measurements were not conducted by a commercial service provider. This limits the

application and dissemination of their metabolomics-based risk models in clinical practice

(27).

A growing body of evidence emphasizes that the associations of some metabolites with

MACE differ in men and women, and deriving sex-specific risk models is a potential way to

enhance the predictive power (28-30). Sex differences in the association with CVD risk of

metabolomic biomarkers are biologically possible due to differences in sex hormones, sex

chromosomes, and lifestyle differences (31-33). For example, 141 out of 179 lipid species

were found to differ significantly between males and females in the Finnish GeneRISK cohort

(28). However, sex-specific analyses are much more demanding in terms of sample size,

which might be the reason why - to our knowledge - there are currently no other studies with

diabetic patients, which derived sex-specific, metabolomics-based cardiovascular risk

prediction models.

Biological mechanisms of selected metabolites

Three metabolites (creatinine, albumin, and GlycA) were chosen to enhance MACE risk

prediction for both sexes, with lactate additionally selected for women, and acetate, VLDL-

size, and Omega-3-pct specifically selected for men. Creatinine and albumin are indicative of

mace renal function. Patients with moderate to severe chronic kidney disease have an increased MACE risk (3; 34). GlycA reflects the glycosylation status of acute phase proteins and thus is a pro-inflammatory biomarker. Inflammatory processes are crucial in the development and progression of cardiovascular diseases (35). Lactate, a key byproduct of glycolysis, is often elevated during metabolic stress. Elevated lactate levels are associated with inflammation, endothelial dysfunction, and oxidative stress (36). Acetate is the most abundant endogenously produced short-chain fatty acid and has been found to be associated with weight loss, enhanced insulin sensitivity, and a reduced cardiovascular risk reduction (37). The size of VLDL particles is an independent predictor of atherosclerosis beyond traditional lipid measurements, highlighting its importance in cardiovascular risk stratification in type 2 diabetes (38). Omega-3 fatty acids are known for their beneficial effects on endothelial function and their role in reducing systemic inflammation (39). If associations of these biomarkers with MACE were not in the expected direction (e.g. for lactate), this might be explained by the comprehensive adjustment for the variables of the SCORE2-Diabetes model.

**Strengths and limitations** 

In terms of strengths, our study stands out for its large sample size (n = 10,257 for UKB, n = 1,039 for ESTHER), making it the largest metabolomics study focused on predicting the cardiovascular risk in individuals with type 2 diabetes so far. Additionally, this study is pioneering in selecting metabolomic biomarkers for cardiovascular risk prediction separately by sex and using an external validation cohort. Furthermore, model calibration was performed for a low risk (UK) and intermediate cardiovascular risk region (Germany).

However, our study has certain limitations. The ESTHER study may not be the ideal external validation cohort for our model due to its differences from the UKB, including a higher mean

age (64 vs. 61.5 years), a higher proportion of fasting of at least 4 hours prior to blood sample

donation (89.1% vs. 23.7%), which can be relevant for some metabolic biomarkers, and the

differences in the ascertainment of non-fatal strokes, which did not allow for the exclusion of

hemorrhagic strokes, as well as the regional difference of cardiovascular risk (low in UK and

intermediate in Germany). These differences could have negatively influenced the results of

the external validation. However, despite these cohort differences, the overall consistency in

risk prediction results between the two cohorts provides support for the robustness of the

derived model. Another limitation was this study may be generalizable to low-to-intermediate

risk regions in Europe, larger validation cohorts are needed, which should originate not only

from low to intermediate risk regions in Europe but shall also validate the new risk model in

populations from high and very high-risk regions.

Potential clinical utility of the derived model

The integration of 7 selected metabolomic biomarkers in the SCORE2-Diabetes model has led

to a significant improvement in the discrimination of 10-year cardiovascular risk in patients

with type 2 diabetes. This augmentation enhances the predictive power of the model without

compromising the convenience offered by the conventional model, which requires only a brief

physical examination, interview, and blood sample analysis.

While incorporating metabolomics into clinical practice does incur costs, it is important to

note that the NMR method used for metabolomic analysis is generally more cost-effective and

standardized compared to the LC-MS/MS (Liquid Chromatography-Mass Spectrometry/Mass

Spectrometry) method (40). Additionally, commercial companies like Nightingale Health are

available to handle large sample sizes in a short time, making this approach feasible for

16

widespread clinical application.

However, before recommending routine measurement in clinical practice, it is essential to

consider country-specific validation of the model. Currently, our algorithm is primarily

validated for the UK and Germany, and extending this validation to other regions is crucial

for broader applicability. The differences in cardiovascular risk profiles and healthcare

systems across countries necessitate such validation to ensure the effectiveness and relevance

of the model in diverse settings.

**Conclusions** 

This investigation showed for the first time with an external validation cohort, that

metabolites can enhance an established MACE prediction model for patients with type 2

diabetes. As metabolomic analyses became standardized and affordable by the NMR

technology in recent years, these measurements have a translation potential for clinical

routine. The developed and validated SCORE2-Diabetes model extended by 7 metabolites can

be used for an improved cardiovascular risk stratification, which is needed for personalized

cardiovascular prevention measures in patients with type 2 diabetes.

List of abbreviations

CI, confidence intervals; CVD, cardiovascular disease; eGFR, estimated glomerular filtration

rate; ESTHER, Epidemiologische Studie zu Chancen der Verhütung, Früherkennung und

optimierten Therapie chronischer Erkrankungen in der älteren Bevölkerung; FDR, false

discovery rat; GlycA, glycoprotein acetyls; GP, general practitioner; HR, hazard ratio; IDI,

integrated discrimination improvement; LASSO, least absolute shrinkage and selection

operator; LC-MS/MS, Liquid Chromatography-Mass Spectrometry;

MACE, major adverse cardiovascular events; MI, myocardial infarction; NMR, nuclear

magnetic resonance; NRI, net reclassification index; Omega-3-pct, the Omega-3 fatty acids

percentage of total fatty acids; SBP, systolic blood pressure; SD, standard deviation; UKB,

UK Biobank; VLDL-size, the average diameter for very low-density lipoprotein particles.

**Article Information** 

Acknowledgements

We would like to thank all participants of the ESTHER and UK Biobank cohort as well as the

GPs of the ESTHER study and the staff of the UK Biobank assessment centers for their

contribution to the studies this research is based on. Part of this research was conducted using

the UK Biobank Resource under application 101633.

**Funding** 

The ESTHER study was funded by the Baden-Württemberg state Ministry of Science,

Research and Arts (Stuttgart, Germany), the Federal Ministry of Education and Research

(Berlin, Germany) and the Federal Ministry of Family Affairs, Senior Citizens, Women and

Youth (Berlin, Germany). UK Biobank was established by the Wellcome Trust, Medical

Research Council, Department of Health, Scottish government, and Northwest Regional

Development Agency. It has also had funding from the Welsh assembly government and the

British Heart Foundation. The sponsors had no role in data acquisition or the decision to

18

publish the data.

**Duality of Interest** 

The authors declare that they have no competing interests.

**Author's Contributions** 

H.B. designed and led the ESTHER cohort. R.X. and B.S. generated the idea for the study and

formulated the analytical plan. R.X. did the data analyses and drafted the manuscript. B.S.

revised it. All authors contributed valuable intellectual content to the discussion. The

corresponding author attests that all listed authors meet authorship criteria and that no others

meeting the criteria have been omitted. H.B. and B.S. had full access to ESTHER data. R.X.

and B.S. had full access to UK Biobank data used for this study. R.X. and B.S. are the

guarantors of the manuscript and accepts full responsibility for the work and/or the conduct of

19

the study.

**Prior Presentation** 

Not applicable.

#### References

- Townsend N, Kazakiewicz D, Lucy Wright F, Timmis A, Huculeci R, Torbica A, Gale CP, Achenbach S, Weidinger F, Vardas P. Epidemiology of cardiovascular disease in Europe. Nat Rev Cardiol 2022;19:133-143
- Sarwar N, Gao P, Seshasai SR, Gobin R, Kaptoge S, Di Angelantonio E, Ingelsson E, Lawlor DA, Selvin E, Stampfer M, Stehouwer CD, Lewington S, Pennells L, Thompson A, Sattar N, White IR, Ray KK, Danesh J. Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies. Lancet 2010;375:2215-2222
- 3. Visseren FL, Mach F, Smulders YM, Carballo D, Koskinas KC, Bäck M, Benetos A, Biffi A, Boavida J-M, Capodanno D. 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice: Developed by the Task Force for cardiovascular disease prevention in clinical practice with representatives of the European Society of Cardiology and 12 medical societies With the special contribution of the European Association of Preventive Cardiology (EAPC). European journal of preventive cardiology 2022;29:5-115
- 4. Pennells L, Kaptoge S, Ostergaard HB, Read SH, Carinci F, Franch-Nadal J, Petitjean C, Taylor O, Hageman SH, Xu Z. SCORE2-Diabetes: 10-year cardiovascular risk estimation in type 2 diabetes in Europe. Eur Heart J 2023;44:2544-2556
- 5. Dziopa K, Asselbergs FW, Gratton J, Chaturvedi N, Schmidt AF. Cardiovascular risk prediction in type 2 diabetes: a comparison of 22 risk scores in primary care settings. Diabetologia 2022;65:644-656
- McGarrah RW, Crown SB, Zhang GF, Shah SH, Newgard CB. Cardiovascular Metabolomics. Circ Res 2018;122:1238-1258
- Cardona A, O'Brien A, Bernier MC, Somogyi A, Wysocki VH, Smart S, He X, Ambrosio G, Hsueh WA, Raman SV. Trimethylamine N-oxide and incident atherosclerotic events in high-risk individuals with diabetes: an ACCORD trial post hoc analysis. BMJ Open Diabetes Res Care 2019;7:e000718
- 8. Dodangeh S, Taghizadeh H, Hosseinkhani S, Khashayar P, Pasalar P, Meybodi HRA, Razi F, Larijani B. Metabolomics signature of cardiovascular disease in patients with diabetes, a narrative review. Journal of Diabetes & Metabolic Disorders 2023;22:985-994

- 9. Harris K, Oshima M, Sattar N, Würtz P, Jun M, Welsh P, Hamet P, Harrap S, Poulter N, Chalmers J, Woodward M. Plasma fatty acids and the risk of vascular disease and mortality outcomes in individuals with type 2 diabetes: results from the ADVANCE study. Diabetologia 2020;63:1637-1647
- 10. Welsh P, Rankin N, Li Q, Mark PB, Würtz P, Ala-Korpela M, Marre M, Poulter N, Hamet P, Chalmers J, Woodward M, Sattar N. Circulating amino acids and the risk of macrovascular, microvascular and mortality outcomes in individuals with type 2 diabetes: results from the ADVANCE trial. Diabetologia 2018;61:1581-1591
- 11. Tabassum R, Widén E, Ripatti S. Effect of biological sex on human circulating lipidome: An overview of the literature. Atherosclerosis 2023:117274
- 12. Vaura F, Palmu J, Aittokallio J, Kauko A, Niiranen T. Genetic, Molecular, and Cellular Determinants of Sex-Specific Cardiovascular Traits. Circ Res 2022;130:611-631
- 13. Sudlow C, Gallacher J, Allen N, Beral V, Burton P, Danesh J, Downey P, Elliott P, Green J, Landray M, Liu B, Matthews P, Ong G, Pell J, Silman A, Young A, Sprosen T, Peakman T, Collins R. UK biobank: an open access resource for identifying the causes of a wide range of complex diseases of middle and old age. PLoS Med 2015;12:e1001779
- 14. Schöttker B, Herder C, Rothenbacher D, Roden M, Kolb H, Müller H, Brenner H. Proinflammatory cytokines, adiponectin, and increased risk of primary cardiovascular events in diabetic patients with or without renal dysfunction: results from the ESTHER study. Diabetes Care 2013;36:1703-1711
- 15. Xuan Y, Gào X, Anusruti A, Holleczek B, Jansen E, Muhlack DC, Brenner H, Schöttker B. Association of Serum Markers of Oxidative Stress With Incident Major Cardiovascular Events, Cancer Incidence, and All-Cause Mortality in Type 2 Diabetes Patients: Pooled Results From Two Cohort Studies. Diabetes Care 2019;42:1436-1445
- Soininen P, Kangas AJ, Würtz P, Suna T, Ala-Korpela M. Quantitative serum nuclear magnetic resonance metabolomics in cardiovascular epidemiology and genetics. Circ Cardiovasc Genet 2015;8:192-206
- 17. Davyson E, Shen X, Gadd DA, Bernabeu E, Hillary RF, McCartney DL, Adams M, Marioni R, McIntosh AM. Metabolomic Investigation of Major Depressive Disorder Identifies a Potentially Causal Association With Polyunsaturated Fatty Acids. Biol Psychiatry Biol Psychiatry. 2024;95(1):93.
- 18. Levey AS, Stevens LA, Schmid CH, Zhang Y, Castro III AF, Feldman HI, Kusek JW, Eggers P, Van Lente F, Greene T. A new equation to estimate glomerular filtration rate. Ann Intern Med 2009;150:604-612
- 19. Niersmann C, Carstensen-Kirberg M, Maalmi H, Holleczek B, Roden M, Brenner H, Herder C, Schöttker B. Higher circulating omentin is associated with increased risk of primary cardiovascular events in individuals with diabetes. Diabetologia 2020;63:410-418
- 20. Stekhoven DJ, Bühlmann P. MissForest--non-parametric missing value imputation for mixed-type data. Bioinformatics 2012;28:112-118

- 21. Tibshirani R. Regression shrinkage and selection via the lasso. Journal of the Royal Statistical Society Series B: Statistical Methodology 1996;58:267-288
- 22. Bach FR. Bolasso: model consistent lasso estimation through the bootstrap. In Proceedings of the 25th international conference on Machine learning. p. 33-40
- 23. Huang Z, Klaric L, Krasauskaite J, Khalid W, Strachan MWJ, Wilson JF, Price JF. Combining serum metabolomic profiles with traditional risk factors improves 10-year cardiovascular risk prediction in people with type 2 diabetes. Eur J Prev Cardiol 2023;30:1255-1262
- 24. van Geloven N, Giardiello D, Bonneville EF, Teece L, Ramspek CL, van Smeden M, Snell KIE, van Calster B, Pohar-Perme M, Riley RD, Putter H, Steyerberg E. Validation of prediction models in the presence of competing risks: a guide through modern methods. BMJ 2022;377:e069249
- 25. Kerr KF, Wang Z, Janes H, McClelland RL, Psaty BM, Pepe MS. Net reclassification indices for evaluating risk-prediction instruments: a critical review. Epidemiology (Cambridge, Mass) 2014;25:114
- 26. Alshehry ZH, Mundra PA, Barlow CK, Mellett NA, Wong G, McConville MJ, Simes J, Tonkin AM, Sullivan DR, Barnes EH, Nestel PJ, Kingwell BA, Marre M, Neal B, Poulter NR, Rodgers A, Williams B, Zoungas S, Hillis GS, Chalmers J, Woodward M, Meikle PJ. Plasma Lipidomic Profiles Improve on Traditional Risk Factors for the Prediction of Cardiovascular Events in Type 2 Diabetes Mellitus. Circulation 2016;134:1637-1650
- 27. Damen JA, Hooft L, Schuit E, Debray TP, Collins GS, Tzoulaki I, Lassale CM, Siontis GC, Chiocchia V, Roberts C, Schlüssel MM, Gerry S, Black JA, Heus P, van der Schouw YT, Peelen LM, Moons KG. Prediction models for cardiovascular disease risk in the general population: systematic review. BMJ 2016;353:i2416
- 28. Tabassum R, Ruotsalainen S, Ottensmann L, Gerl MJ, Klose C, Tukiainen T, Pirinen M, Simons K, Widén E, Ripatti S. Lipidome- and Genome-Wide Study to Understand Sex Differences in Circulatory Lipids. J Am Heart Assoc 2022;11:e027103
- 29. Mittelstrass K, Ried JS, Yu Z, Krumsiek J, Gieger C, Prehn C, Roemisch-Margl W, Polonikov A, Peters A, Theis FJ, Meitinger T, Kronenberg F, Weidinger S, Wichmann HE, Suhre K, Wang-Sattler R, Adamski J, Illig T. Discovery of sexual dimorphisms in metabolic and genetic biomarkers. PLoS Genet 2011;7:e1002215
- 30. Würtz P, Havulinna AS, Soininen P, Tynkkynen T, Prieto-Merino D, Tillin T, Ghorbani A, Artati A, Wang Q, Tiainen M, Kangas AJ, Kettunen J, Kaikkonen J, Mikkilä V, Jula A, Kähönen M, Lehtimäki T, Lawlor DA, Gaunt TR, Hughes AD, Sattar N, Illig T, Adamski J, Wang TJ, Perola M, Ripatti S, Vasan RS, Raitakari OT, Gerszten RE, Casas JP, Chaturvedi N, Ala-Korpela M, Salomaa V. Metabolite profiling and cardiovascular event risk: a prospective study of 3 population-based cohorts. Circulation 2015;131:774-785
- 31. Murphy E. Estrogen signaling and cardiovascular disease. Circ Res 2011;109:687-696

- 32. Carrel L, Willard HF. X-inactivation profile reveals extensive variability in X-linked gene expression in females. Nature 2005;434:400-404
- 33. Shankar RR, Charchar FJ, Eckert GJ, Saha C, Tu W, Dominiczak AF, Pratt JH. Studies of an association in boys of blood pressure and the Y chromosome. Am J Hypertens 2007;20:27-31
- 34. Matsushita K, Kaptoge S, Hageman SHJ, Sang Y, Ballew SH, Grams ME, Surapaneni A, Sun L, Arnlov J, Bozic M, Brenner H, Brunskill NJ, Chang AR, Chinnadurai R, Cirillo M, Correa A, Ebert N, Eckardt K-U, Gansevoort RT, Gutierrez O, Hadaegh F, He J, Hwang S-J, Jafar TH, Jassal SK, Kayama T, Kovesdy CP, Landman GW, Levey AS, Lloyd-Jones DM, Major RW, Miura K, Muntner P, Nadkarni GN, Nowak C, Ohkubo T, Pena MJ, Polkinghorne KR, Sairenchi T, Schaeffner E, Schneider MP, Shalev V, Shlipak MG, Solbu MD, Stempniewicz N, Tollitt J, Valdivielso JM, van der Leeuw J, Wang AY-M, Wen C-P, Woodward M, Yamagishi K, Yatsuya H, Zhang L, Dorresteijn JAN, Di Angelantonio E, Visseren FLJ, Pennells L, Coresh J. Including measures of chronic kidney disease to improve cardiovascular risk prediction by SCORE2 and SCORE2-OP. European Journal of Preventive Cardiology 2022;30:8-16
- 35. Connelly MA, Otvos JD, Shalaurova I, Playford MP, Mehta NN. GlycA, a novel biomarker of systemic inflammation and cardiovascular disease risk. J Transl Med 2017;15:219
- 36. Li X, Yang Y, Zhang B, Lin X, Fu X, An Y, Zou Y, Wang JX, Wang Z, Yu T. Lactate metabolism in human health and disease. Signal Transduct Target Ther 2022;7:305
- 37. Hernández MAG, Canfora EE, Jocken JWE, Blaak EE. The Short-Chain Fatty Acid Acetate in Body Weight Control and Insulin Sensitivity. Nutrients 2019;11
- 38. Amor AJ, Catalan M, Pérez A, Herreras Z, Pinyol M, Sala-Vila A, Cofán M, Gilabert R, Ros E, Ortega E. Nuclear magnetic resonance lipoprotein abnormalities in newly-diagnosed type 2 diabetes and their association with preclinical carotid atherosclerosis. Atherosclerosis 2016;247:161-169
- 39. Shahidi F, Ambigaipalan P. Omega-3 Polyunsaturated Fatty Acids and Their Health Benefits. Annu Rev Food Sci Technol 2018;9:345-381
- 40. Jacob M, Lopata AL, Dasouki M, Abdel Rahman AM. Metabolomics toward personalized medicine. Mass Spectrom Rev 2019;38:221-238

### Figure legends

**Figure 1.** Associations between selected metabolites and major cardiovascular events across sexes in the derivation set (70% of UK biobank, N=7,180)

**Abbreviations:** CI, confidence interval; FDR, false discovery rate; GlycA, glycoprotein acetyls; HR, hazard ratio; Omega-3-pct, Omega-3 fatty acids to total fatty acids percentage; SD, standard deviation; VLDL-size, average diameter for very-low-density lipoprotein particles.

<sup>a</sup> Hazard ratios are expressed per 1 standard deviation of the respective metabolite concentration and are adjusted for age, systolic blood pressure, smoking status, diabetes age at diagnosis, glycated hemoglobin, and the estimated glomerular filtration rate. The standard deviations of creatinine, albumin, GlycA, acetate, omega-3-pct, VLDL-size, and lactate were 0.02 mmol/L, 3.60 mmol/L, 0.13 mmol/L, 0.04 mmol/L, 1.51%, 1.41 mmol/L, and 1.23 mmol/L, respectively.

**Figure 2.** The incremental discrimination of each metabolite for the model after the selected metabolites were added to SCORE2-Diabetes separately in different sexes in the internal validation set (30% of UK Biobank, N=3,077)

**Abbreviations:** CI, confidence interval; GlycA, glycoprotein acetyls; HR, hazard ratio; Omega-3-pct, Omega-3 fatty acids to total fatty acids percentage; VLDL-size, average diameter for very-low-density lipoprotein particles.

**Table 1.** Baseline characteristics of selected participants with type 2 diabetes from the UK Biobank and ESTHER study

UK Biobank (n=10,257)	ESTHER (n=1,039)
6,140 (59.9)	528 (50.8)
61.5 (5.2)	64.0 (6.3)
1,024 (10.0)	157 (15.7)
144.8 (18.2)	144.2 (19.5)
3.7 (0.9)	5.6 (1.1)
1.1 (0.3)	1.3 (0.3)
55.4 (6.4)	55.6 (5.7)
51.8 (12.8)	53.1 (14.4)
87.7 (15.4)	78.6 (17.7)
	6,140 (59.9) 61.5 (5.2) 1,024 (10.0) 144.8 (18.2) 3.7 (0.9) 1.1 (0.3) 55.4 (6.4) 51.8 (12.8)

<sup>&</sup>lt;sup>a</sup> The eGFR was calculated with the CKD-EPI 2009 equation.

**Abbreviations:** eGFR, estimated Glomerular Filtration Rate; HbA<sub>1c</sub>, glycated hemoglobin; HDL, high-density lipoprotein; IQR, interquartile range; SD, standard deviation.

**Table 2.** Metrics of the predictive performance of the SCORE2-Diabetes model for 10-year MACE risk without and with extension by metabolites


Metrics	Men	Women	Overall
Derivation set (70% of UK Biobank)			
Total sample size / MACE cases	4,298/691	2,882/249	7,180/940
C-index (SCORE2-Diabetes)	0.630 (0.606,0.653)	0.673 (0.638,0.707)	0.662 (0.644,0.681)
C-index (+Metabolites <sup>a,b</sup> )	0.647 (0.624,0.670)	0.680 (0.645, 0.714)	0.677 (0.659,0.696)
P-values for C-index comparisons	0.020	0.053	0.008
Internal validation set (30% of UK B	siobank)		
Total sample size / MACE cases	1,842/313	1,235/113	3,077/426
C-index (SCORE2-Diabetes)	0.632 (0.597, 0.668)	0.670 (0.617, 0.722)	0.660 (0.632, 0.688)
C-index (+Metabolites <sup>a,b</sup> )	0.657 (0.623,0.692)	0.679 (0.625,0.733)	0.680 (0.652,0.708)
P-values for C-index comparisons	0.005	0.716	0.034
NRI <sup>c</sup> total (%)	0.9 (-7.4, 9.3)	7.0 (-8.8, 24.5)	5.6 (-2.5, 13.8)
NRI <sup>c</sup> events (%)	3.6 (-4.0, 7.5)	2.3 (-14.0, 26.9)	0.6 (-3.8, 7.9)
NRI <sup>c</sup> non-events (%)	-2.7 (-7.7, 3.8)	4.7 (-4.5, 12.6)	5.0 (-1.8, 8.8)
IDI	0.000 (-0.015, 0.014)	0.024 (0.002, 0.053)	0.013 (0.001, 0.026)
External validation set (ESTHER)			
Total sample size / MACE cases	528/107	511/68	1,039/175
C-index (SCORE2-Diabetes)	0.632 (0.573,0.691)	0.618 (0.545,0.691)	0.612 (0.566,0.657)
C-index (+Metabolites <sup>a,b</sup> )	0.663 (0.608, 0.719)	0.648 (0.575, 0.721)	0.653 (0.609, 0.697)
P-values for C-index comparisons	0.178	0.241	0.015
NRI <sup>c</sup> total (%)	7.6 (-6.5, 16.0)	-6.9 (-23.7, 16.9)	4.3 (-5.7, 12.9)
NRI <sup>c</sup> events (%)	9.6 (0.9, 16.1)	-3.0 (-16.0, 15.7)	4.3 (-4.0, 10.5)
NRI <sup>c</sup> non-events (%)	-2.0 (-16.5, 10.2)	-3.9 (-17.4, 10.5)	0.0 (-7.9, 8.7)
IDI	0.004 (-0.025, 0.036)	0.000 (-0.032, 0.042)	0.010 (-0.007, 0.030)


**Abbreviations:** IDI, integrated discrimination improvement; MACE, major cardiovascular events; NRI, net reclassification improvement.

<sup>&</sup>lt;sup>a</sup> Metabolites that were included in the combined model for men were creatinine, albumin, GlycA, acetate, Omega-3-pct, and VLDL-size.

<sup>&</sup>lt;sup>b</sup> Metabolites that were included in the combined model for women were lactate, creatinine, albumin, and GlycA.

<sup>&</sup>lt;sup>c</sup> NRI calculated with the pre-specified 10-year MACE risk categories of 0–10%, >10–20%, and >20%.







# Improving 10-year cardiovascular risk prediction in patients with type 2 diabetes with metabolomics


# **Study cohorts**

Derivation cohort **UK Biobank** N=10,257 Validation cohort **ESTHER** N=1,039





## **Model derivation**



### **Performance evaluations**

Base model:

**SCORE2-Diabetes** 

**Outcomes:** 

10-year MACE risk





**Discrimination (C-index) Internal validation** 

SCORE2-Diabetes: 0.660

Extended by metabolomics: 0.680

 $\Delta$ C-index: +0.020; P = 0.034

**Discrimination (C-index) External validation** 

SCORE2-Diabetes: 0.612

Extended by metabolomics: 0.653

 $\Delta$ C-index: +0.041: P = 0.015